Authors
Jonathan M Loree, Seerat Anand, Arvind Dasari, Joseph M Unger, Anirudh Gothwal, Lee M Ellis, Gauri Varadhachary, Scott Kopetz, Michael J Overman, Kanwal Raghav
Publication date
2019/10/1
Journal
JAMA oncology
Volume
5
Issue
10
Pages
e191870-e191870
Publisher
American Medical Association
Description
Importance
Representative racial/ethnic participation in research, especially in clinical trials that establish standards of care, is necessary to minimize disparities in outcomes and to uphold societal equity in health care.
Objective
To evaluate the frequency of race reporting and proportional race representation in trials supporting US Food and Drug Administration (FDA) oncology drug approvals.
Design, Setting, and Participants
Database study of all reported trials supporting FDA oncology drug approvals granted between July 2008 and June 2018. Primary reports of trials were obtained from PubMed and ClinicalTrials.gov. Food and Drug Administration approvals were identified using the FDA archives. The US population-based cancer estimates by race were calculated using National Cancer Institute–Surveillance, Epidemiology, and End Results and US Census databases.
Main Outcomes and Measures
Primary …
Scholar articles
JM Loree, S Anand, A Dasari, JM Unger, A Gothwal… - JAMA oncology, 2019